“Long-term Efficacy and Safety of Brodalumab in Patients With Psoriasis Whose Disease Did Not Respond to Prior Biologics”, J of Skin, vol. 3, p. S22, Nov. 2019, doi: 10.25251/skin.3.supp.22.